{
    "download_date": [
        "ClinicalTrials.gov processed this data on May 09, 2023"
    ],
    "link_text": [
        "Link to the current ClinicalTrials.gov record."
    ],
    "url": [
        "https://clinicaltrials.gov/show/NCT05389722",
        "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html",
        "https://www.bmsstudyconnect.com/s/US/English/USenHome",
        "https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"
    ],
    "org_study_id": [
        "CA057-002"
    ],
    "nct_id": [
        "NCT05389722"
    ],
    "brief_title": [
        "A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants"
    ],
    "official_title": [
        "A Phase 1, Parallel-group, 3-part, 2-period, Fixed-sequence, Crossover, Open-label, Nonrandomized, Drug-drug Interaction Study to Assess the Pharmacokinetics of CC-92480 (BMS-986348) After Coadministration With Rifampin and Itraconazole, and Pharmacokinetics of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants"
    ],
    "lead_sponsor": [],
    "source": [
        "Bristol-Myers Squibb"
    ],
    "has_dmc": [
        "No"
    ],
    "is_fda_regulated_drug": [
        "Yes"
    ],
    "is_fda_regulated_device": [
        "No"
    ],
    "textblock": [
        "The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration\r\n      with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after\r\n      coadministration with CC-92480 in healthy participants."
    ],
    "overall_status": [
        "Completed"
    ],
    "type": [
        "Actual",
        "Actual",
        "Actual",
        "Actual",
        "Actual",
        "Actual"
    ],
    "start_date": [
        "June 9, 2022"
    ],
    "completion_date": [
        "November 12, 2022"
    ],
    "primary_completion_date": [
        "November 12, 2022"
    ],
    "phase": [
        "Phase 1"
    ],
    "study_type": [
        "Interventional"
    ],
    "has_expanded_access": [
        "No"
    ],
    "allocation": [
        "Non-Randomized"
    ],
    "intervention_model": [
        "Parallel Assignment"
    ],
    "primary_purpose": [
        "Treatment"
    ],
    "masking": [
        "None (Open Label)"
    ],
    "measure": [
        "Maximum observed plasma concentration (Cmax)",
        "Time of maximum observed plasma concentration (Tmax)",
        "Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))",
        "Number of participants with adverse events (AEs)",
        "Number of participants with physical examination findings",
        "Number of participants with vital sign abnormalities",
        "Number of participants with 12-lead electrocardiogram (ECG) abnormalities",
        "Number of participants with clinical laboratory abnormalities"
    ],
    "time_frame": [
        "Up to 2 months",
        "Up to 2 months",
        "Up to 2 months",
        "Up to 3 months",
        "Up to 3 months",
        "Up to 3 months",
        "Up to 3 months",
        "Up to 3 months"
    ],
    "number_of_arms": [
        3.0
    ],
    "enrollment": [
        24.0
    ],
    "condition": [
        "Healthy Volunteers"
    ],
    "arm_group_label": [
        "Part 1",
        "Part 2",
        "Part 3",
        "Part 3",
        "Part 1",
        "Part 2",
        "Part 3",
        "Part 3"
    ],
    "arm_group_type": [
        "Experimental",
        "Experimental",
        "Experimental"
    ],
    "intervention_type": [
        "Drug",
        "Drug",
        "Drug",
        "Drug",
        "Drug"
    ],
    "intervention_name": [
        "CC-92480",
        "Rifampin",
        "Itraconazole",
        "Digoxin",
        "Rosuvastatin"
    ],
    "description": [
        "Specified dose on specified days",
        "Specified dose on specified days",
        "Specified dose on specified days",
        "Specified dose on specified days",
        "Specified dose on specified days",
        "BMS Clinical Trial Information",
        "BMS Clinical Trial Patient Recruiting",
        "FDA Safety Alerts and Recalls"
    ],
    "other_name": [
        "BMS-986348"
    ],
    "criteria": [],
    "gender": [
        "All"
    ],
    "minimum_age": [
        "18 Years"
    ],
    "maximum_age": [
        "55 Years"
    ],
    "healthy_volunteers": [
        "Accepts Healthy Volunteers"
    ],
    "last_name": [
        "Bristol-Myers Squibb"
    ],
    "role": [
        "Study Director"
    ],
    "affiliation": [
        "Bristol-Myers Squibb"
    ],
    "facility": [],
    "country": [
        "United States"
    ],
    "verification_date": [
        "April 2023"
    ],
    "study_first_submitted": [
        "May 20, 2022"
    ],
    "study_first_submitted_qc": [
        "May 20, 2022"
    ],
    "study_first_posted": [
        "May 25, 2022"
    ],
    "last_update_submitted": [
        "April 18, 2023"
    ],
    "last_update_submitted_qc": [
        "April 18, 2023"
    ],
    "last_update_posted": [
        "April 19, 2023"
    ],
    "responsible_party_type": [
        "Sponsor"
    ],
    "keyword": [
        "CC-92480",
        "Healthy Volunteer",
        "Pharmacokinetic"
    ],
    "mesh_term": [
        "Rosuvastatin Calcium"
    ]
}